Form 4: Nordicus Partners Corp. Discloses Share Transactions and Acquisitions
Ownership Disclosure
Nordicus Partners Corp. has reported several share transactions, including acquisitions of Bio-Convert ApS and Orocidin A/S, along with warrant exercises.
Summary
- Nordicus Partners Corp. has disclosed multiple transactions involving its common stock and warrants.
- These transactions include the purchase of 500 shares on September 3, 2024, and 5,000 shares on October 1, 2024.
- A significant acquisition of 1,076,412 shares occurred on November 12, 2024, related to the acquisitions of Bio-Convert ApS (893,268 shares) and Orocidin A/S (183,144 shares).
- Several warrant exercises were also reported, with varying amounts of shares acquired at a price of $10.00 per share.
- The warrant exercises occurred between August 30, 2024, and November 6, 2024, with the number of shares ranging from 3,200 to 12,000.
Sentiment
Score: 7
Explanation: The document indicates strategic growth through acquisitions and investor confidence through warrant exercises, suggesting a positive outlook, but lacks financial details to give a higher score.
Positives
- The acquisitions of Bio-Convert ApS and Orocidin A/S indicate strategic growth for Nordicus Partners Corp.
- The warrant exercises suggest investor confidence in the company's future.
Risks
- The document does not provide any information about the financial performance of the acquired companies.
- The document does not provide any information about the impact of the warrant exercises on the company's share structure.
Industry Context
The acquisitions of Bio-Convert ApS and Orocidin A/S suggest a strategic move by Nordicus Partners Corp. to expand its business through mergers and acquisitions, which is a common strategy in many industries.
Comparison to Industry Standards
- The document does not provide enough information to compare the results to industry standards.
- Without knowing the specific industry of Nordicus Partners Corp. and the financial performance of the acquired companies, it is difficult to assess the significance of these transactions.
Stakeholder Impact
- Shareholders will see an increase in the number of outstanding shares due to the acquisitions and warrant exercises.
- The acquisitions may lead to new opportunities for employees of Nordicus Partners Corp. and the acquired companies.
Key Dates
| Date | Description |
|---|---|
| 2022-04-01 | Start date for warrant exercises. |
| 2023-12-31 | End date for warrant exercises. |
| 2024-08-30 | Date of initial share and warrant transactions. |
| 2024-09-03 | Purchase of 500 common shares. |
| 2024-10-01 | Purchase of 5,000 common shares. |
| 2024-10-03 | Warrant exercise for 3,200 shares. |
| 2024-10-17 | Warrant exercise for 12,000 shares. |
| 2024-11-01 | Warrant exercise for 3,500 shares. |
| 2024-11-06 | Warrant exercise for 3,500 shares. |
| 2024-11-12 | Acquisition of 1,076,412 shares through Bio-Convert ApS and Orocidin A/S acquisitions. |
| 2024-12-10 | Date of signature by Tom Glaesner Larsen. |
Keywords
Nordicus Partners Corp, share acquisition, warrant exercise, Bio-Convert ApS, Orocidin A/S, common stock, share exchange
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.